9
31/03/2024
2024-03-31
false
false
false
false
false
false
false
true
false
false
true
false
false
false
true
false
true
false
No description of principal activities is disclosed
2023-04-01
Sage Accounts Production 24.0 - FRS102_2021
xbrli:pure
xbrli:shares
iso4217:GBP
04654503
2023-04-01
2024-03-31
04654503
2024-03-31
04654503
2023-03-31
04654503
2022-04-01
2023-03-31
04654503
2023-03-31
04654503
2022-03-31
04654503
core:PlantMachinery
2023-04-01
2024-03-31
04654503
core:MotorVehicles
2023-04-01
2024-03-31
04654503
core:NetGoodwill
2023-04-01
2024-03-31
04654503
bus:RegisteredOffice
2023-04-01
2024-03-31
04654503
bus:LeadAgentIfApplicable
2023-04-01
2024-03-31
04654503
bus:Director1
2023-04-01
2024-03-31
04654503
core:NetGoodwill
2024-03-31
04654503
core:FurnitureFittingsToolsEquipment
2023-03-31
04654503
core:FurnitureFittingsToolsEquipment
2024-03-31
04654503
core:MotorVehicles
2024-03-31
04654503
core:WithinOneYear
2024-03-31
04654503
core:WithinOneYear
2023-03-31
04654503
core:AfterOneYear
2024-03-31
04654503
core:AfterOneYear
2023-03-31
04654503
core:ShareCapital
2024-03-31
04654503
core:ShareCapital
2023-03-31
04654503
core:RetainedEarningsAccumulatedLosses
2024-03-31
04654503
core:RetainedEarningsAccumulatedLosses
2023-03-31
04654503
core:FurnitureFittingsToolsEquipment
2023-04-01
2024-03-31
04654503
core:NetGoodwill
2023-03-31
04654503
core:FurnitureFittingsToolsEquipment
2023-03-31
04654503
bus:Director1
2023-03-31
04654503
bus:Director1
2024-03-31
04654503
bus:Director1
2022-03-31
04654503
bus:Director1
2023-03-31
04654503
bus:Director1
2022-04-01
2023-03-31
04654503
bus:SmallEntities
2023-04-01
2024-03-31
04654503
bus:AuditExempt-NoAccountantsReport
2023-04-01
2024-03-31
04654503
bus:FullAccounts
2023-04-01
2024-03-31
04654503
bus:SmallCompaniesRegimeForAccounts
2023-04-01
2024-03-31
04654503
bus:PrivateLimitedCompanyLtd
2023-04-01
2024-03-31
Company registration number:
04654503
Fields Pharmacy Limited
Unaudited filleted financial statements
31 March 2024
Fields Pharmacy Limited
Contents
Directors and other information
Statement of financial position
Notes to the financial statements
Fields Pharmacy Limited
Directors and other information
|
|
|
|
Director |
Mrs Nasim A Ladak |
|
|
|
|
|
|
|
Company number |
04654503 |
|
|
|
|
|
|
|
Registered office |
38-40 Eldred Avenue |
|
|
Westdene |
|
|
Brighton |
|
|
East Sussex |
|
|
BN1 5EG |
|
|
|
|
|
|
|
Business address |
38-40 Eldred Avenue |
|
|
Westdene |
|
|
Brighton |
|
|
East Sussex |
|
|
BN1 5EG |
|
|
|
|
|
|
|
Accountants |
Pritchard Fellows & Co Ltd |
|
|
Avery House |
|
|
8 Avery Hill Road |
|
|
London |
|
|
SE9 2BD |
|
|
|
Fields Pharmacy Limited
Statement of financial position
31 March 2024
|
|
|
2024 |
|
|
|
2023 |
|
|
|
|
Note |
£ |
|
£ |
|
£ |
|
£ |
|
|
|
|
|
|
|
|
|
|
Fixed assets |
|
|
|
|
|
|
|
|
|
Intangible assets |
|
5 |
420,000 |
|
|
|
420,000 |
|
|
Tangible assets |
|
6 |
20,417 |
|
|
|
5,721 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
|
|
|
|
440,417 |
|
|
|
425,721 |
|
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
|
Stocks |
|
|
55,617 |
|
|
|
55,531 |
|
|
Debtors |
|
7 |
504,201 |
|
|
|
375,026 |
|
|
Cash at bank and in hand |
|
|
57,271 |
|
|
|
43,978 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
|
|
617,089 |
|
|
|
474,535 |
|
|
Creditors: amounts falling due |
|
|
|
|
|
|
|
|
|
within one year |
|
8 |
(
639,328) |
|
|
|
(
519,894) |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
Net current liabilities |
|
|
|
|
(
22,239) |
|
|
|
(
45,359) |
|
|
|
|
|
_______ |
|
|
|
_______ |
Total assets less current liabilities |
|
|
|
|
418,178 |
|
|
|
380,362 |
|
|
|
|
|
|
|
|
|
|
Creditors: amounts falling due |
|
|
|
|
|
|
|
|
|
after more than one year |
|
9 |
|
|
(
106,500) |
|
|
|
(
106,500) |
|
|
|
|
|
_______ |
|
|
|
_______ |
Net assets |
|
|
|
|
311,678 |
|
|
|
273,862 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
|
|
|
|
|
|
|
Capital and reserves |
|
|
|
|
|
|
|
|
|
Called up share capital |
|
|
|
|
100 |
|
|
|
100 |
Profit and loss account |
|
|
|
|
311,578 |
|
|
|
273,762 |
|
|
|
|
|
_______ |
|
|
|
_______ |
Shareholder funds |
|
|
|
|
311,678 |
|
|
|
273,862 |
|
|
|
|
|
_______ |
|
|
|
_______ |
|
|
|
|
|
|
|
|
|
|
For the year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
-
The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
-
The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.
These financial statements were approved by the
board of directors
and authorised for issue on
26 March 2025
, and are signed on behalf of the board by:
Mrs Nasim A Ladak
Director
Company registration number:
04654503
Fields Pharmacy Limited
Notes to the financial statements
Year ended 31 March 2024
1.
General information
The company is a private company limited by shares, registered in United Kingdom. The address of the registered office is Fields Pharmacy Limited, 38-40 Eldred Avenue, Westdene, Brighton, East Sussex, BN1 5EG.
2.
Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3.
Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Turnover
Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in thereporting period. Tax is recognised in the statement of comprehensive income, except to the extent thatit relates to items recognised in other comprehensive income or directly in capital and reserves. In thiscase, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.Current tax is recognised on taxable profit for the current and past periods. Current tax is measured atthe amounts of tax expected to pay or recover using the tax rates and laws that have been enacted orsubstantively enacted at the reporting date.
Goodwill
The goodwill is considered to have an indefinite life that can be demonstrated, and can be readily measured. The dispensing chemist industry, in which the company operates, has high market entry barriers due to the nature of licence agreements with local health authorities and the limited number available in the marketplace. The value of the business can be ascertained by reference to the current value of goodwill which is payable in the market based on a price per £ in relation to the levels of turnover for each individual pharmacy. The director reviews the value of goodwill on an annual basis and considers it to be worth in excess of net book value.
Tangible assets
tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
|
|
|
|
|
|
Plant and machinery |
- |
10 % |
straight line |
|
Motor vehicles |
- |
25 % |
reducing balance |
|
|
|
|
|
If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.
Stocks
Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.
Share-based payments
Equity-settled share-based payment transactions are measured at fair value at the date of grant. The fair value is expensed on a straight-line basis over the vesting period, with a corresponding increase in equity. This is based upon the company's estimate of the shares or share options that will eventually vest which takes into account all vesting conditions and non-market performance conditions, with adjustments being made where new information indicates the number of shares or share options expected to vest differs from previous estimates. Fair value is determined using an appropriate pricing model. All market conditions and non-vesting conditions are taken into account when estimating the fair value of the shares or share options. As long as all other vesting conditions are satsfied, no adjustment is made irrespective of whether market or non-vesting conditions are met. Where the terms of an equity-settled transaction are modified, an expense is recognised as if the terms had not been modified. In addition, an expense is recognised for any increase in the fair value of the transaction, as measured at the date of modification. Where an equity-settled transaction is cancelled or settled, it is treated as if it had vested on the date of cancellation or settlement, and any expense not yet recognised in profit or loss is expensed immediately. Cash-settled share-based payment transactions are measured at the fair value of the liability. Until the liability is settled, the fair value of the liability is re-measured at each reporting date and at the date of settlement, with any changes in fair value recognised in profit or loss for the period.
Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.
Trade debtors
Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business. Trade debtors are recognised initially at the transaction price. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.
Trade creditors
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
4.
Employee numbers
The average number of persons employed by the company during the year amounted to
9
(2023:
9
).
5.
Intangible assets
|
|
Goodwill |
|
|
|
|
|
|
|
£ |
|
|
|
|
|
|
Cost |
|
|
|
|
|
|
|
At 1 April 2023 and 31 March 2024 |
420,000 |
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
Amortisation |
|
|
|
|
|
|
|
At 1 April 2023 and 31 March 2024 |
- |
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
Carrying amount |
|
|
|
|
|
|
|
At 31 March 2024 |
420,000 |
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
At 31 March 2023 |
420,000 |
|
|
|
|
|
|
|
_______ |
|
|
|
|
|
|
|
|
|
|
|
|
|
6.
Tangible assets
|
|
Fixtures, fittings and equipment |
Motor vehicles |
Total |
|
|
|
|
|
|
£ |
£ |
£ |
|
|
|
|
|
Cost |
|
|
|
|
|
|
|
|
At 1 April 2023 |
39,279 |
- |
39,279 |
|
|
|
|
|
Additions |
- |
20,983 |
20,983 |
|
|
|
|
|
|
_______ |
_______ |
_______ |
|
|
|
|
|
At 31 March 2024 |
39,279 |
20,983 |
60,262 |
|
|
|
|
|
|
_______ |
_______ |
_______ |
|
|
|
|
|
Depreciation |
|
|
|
|
|
|
|
|
At 1 April 2023 |
33,558 |
- |
33,558 |
|
|
|
|
|
Charge for the year |
1,041 |
5,246 |
6,287 |
|
|
|
|
|
|
_______ |
_______ |
_______ |
|
|
|
|
|
At 31 March 2024 |
34,599 |
5,246 |
39,845 |
|
|
|
|
|
|
_______ |
_______ |
_______ |
|
|
|
|
|
Carrying amount |
|
|
|
|
|
|
|
|
At 31 March 2024 |
4,680 |
15,737 |
20,417 |
|
|
|
|
|
|
_______ |
_______ |
_______ |
|
|
|
|
|
At 31 March 2023 |
5,721 |
- |
5,721 |
|
|
|
|
|
|
_______ |
_______ |
_______ |
|
|
|
|
|
|
|
|
|
|
|
|
|
7.
Debtors
|
|
|
2024 |
2023 |
|
|
|
£ |
£ |
|
Trade debtors |
|
74,126 |
78,846 |
|
Other debtors |
|
430,075 |
296,180 |
|
|
|
_______ |
_______ |
|
|
|
504,201 |
375,026 |
|
|
|
_______ |
_______ |
|
|
|
|
|
8.
Creditors: amounts falling due within one year
|
|
|
2024 |
2023 |
|
|
|
£ |
£ |
|
Trade creditors |
|
132,021 |
134,065 |
|
Corporation tax |
|
5,595 |
8,045 |
|
Social security and other taxes |
|
4,975 |
785 |
|
Other creditors |
|
496,737 |
376,999 |
|
|
|
_______ |
_______ |
|
|
|
639,328 |
519,894 |
|
|
|
_______ |
_______ |
|
|
|
|
|
9.
Creditors: amounts falling due after more than one year
|
|
|
2024 |
2023 |
|
|
|
£ |
£ |
|
Other creditors |
|
106,500 |
106,500 |
|
|
|
_______ |
_______ |
|
|
|
|
|
10.
Directors advances, credits and guarantees
|
During the year the director entered into the following advances and credits with the company: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2024 |
|
|
|
|
|
|
|
|
|
Balance brought forward |
Advances /(credits) to the director |
Balance o/standing |
|
|
|
|
|
£ |
£ |
£ |
|
|
|
|
Mrs Nasim A Ladak |
(
362,487) |
(
119,630) |
(
482,117) |
|
|
|
|
|
_______ |
_______ |
_______ |
|
|
|
|
|
|
|
|
|
|
|
2023 |
|
|
|
|
|
|
|
|
|
Balance brought forward |
Advances /(credits) to the director |
Balance o/standing |
|
|
|
|
|
£ |
£ |
£ |
|
|
|
|
Mrs Nasim A Ladak |
(
337,316) |
(
25,171) |
(
362,487) |
|
|
|
|
|
_______ |
_______ |
_______ |
|
|
|
|
|
|
|
|
|
|
|
The loan is interest free and repayable on demand.
11.
Controlling party
The director controlled the company throughout the period.